Sequential Androgen Receptor Pathway Inhibitor in Prostate Cancer: Piling-Up The Benefits or a Case for Cross-Resistance?
In the last 10 years, there has been accumulating evidence that, even in a low serum testosterone environment, the androgen receptor (AR) remains the main driver of prostate cancer progression. This has led to the discovery and clinical development of new anti-androgens and androgen biosynthesis inh...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
European Medical Journal
2014-11-01
|
| Series: | European Medical Journal Oncology |
| Subjects: | |
| Online Access: | http://emjreviews.com/wp-content/uploads/Sequential-Androgen-Receptor-Pathway-Inhibitor-in-Prostate-Cancer-Piling-Up-The-Benefits-or-a-Case-for-Cross-Resistance.pdf |